Finding a rational approach to ESA therapy--for payers and patients.
Messana
Anthony
A
St Joseph Hospital, Orange, Calif., USA.
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D014487:Centers for Medicare and Medicaid Services, U.S.; D016527:Drug Costs; D016903:Drug Monitoring; D004363:Drug Utilization; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use; D006270:Health Facility Administrators; D006397:Hematinics / Q000191:economics / Q000627:therapeutic use; D006400:Hematocrit; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D006278:Medicare / Q000191:economics*; D009398:Nephrology; D009936:Organizational Innovation; D012051:Reimbursement Mechanisms / Q000458:organization & administration*; D006435:Renal Dialysis; D012958:Societies, Scientific; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin